Free Trial

BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts

BioMarin Pharmaceutical logo
$65.89
-0.79 (-1.18%)
(As of 10/31/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Feb. 27Estimated
Actual EPS
(Oct. 29)
$0.55 Missed By -$0.23
Consensus EPS
(Oct. 29)
$0.78
Skip Charts & View Estimated and Actual Earnings Data

BMRN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BMRN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioMarin Pharmaceutical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242$0.36$0.36$0.36 
Q2 20242$0.36$0.61$0.49 
Q3 20243$0.53$0.71$0.65 
Q4 20243$0.55$0.71$0.63 
FY 202410$1.80$2.39$2.12 
Q1 20253$0.49$0.71$0.60 
Q2 20253$0.61$0.83$0.75 
Q3 20253$0.65$0.85$0.78 
Q4 20253$0.66$0.87$0.79 
FY 202512$2.41$3.26$2.92 
Q1 20261$0.73$0.73$0.73 
Q2 20261$0.80$0.80$0.80 

BMRN Earnings Date and Information

BioMarin Pharmaceutical last announced its earnings results on October 29th, 2024. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by $0.23. The firm had revenue of $746 million for the quarter, compared to the consensus estimate of $703.37 million. Its quarterly revenue was up 28.4% on a year-over-year basis. BioMarin Pharmaceutical has generated $1.07 earnings per share over the last year ($1.07 diluted earnings per share) and currently has a price-to-earnings ratio of 49.5. Earnings for BioMarin Pharmaceutical are expected to grow by 34.31% in the coming year, from $2.39 to $3.21 per share. BioMarin Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off prior year's report dates.

BioMarin Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/27/2025
(Estimated)
------- 
10/29/2024Q3 2024$0.78$0.55($0.23)$0.93$703.37 million$746.00 million          
8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51 million$712.03 million
4/24/2024Q1 2024$0.37$0.49+$0.12$0.52$649.75 million$648.83 million    
2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53 million$646.21 million          
11/1/2023Q3 2023$0.28$0.26($0.02)$0.31$603.51 million$581.33 million    
7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46 million$595.28 million    
4/26/2023Q1 2023$0.24$0.39+$0.15$0.51$572.53 million$596.42 million    
2/27/2023Q4 2022$0.12$0.11($0.01)$0.22$533.88 million$537.54 million    
10/26/2022Q3 2022$0.12$0.16+$0.04$0.36$516.03 million$505.30 million        
8/3/2022Q2 2022$0.20$0.33+$0.13$0.51$514.18 million$533.80 million        
4/27/2022Q1 2022$0.15$0.31+$0.16($0.01)$505.11 million$519.36 million        
2/23/2022Q4 2021($0.22)($0.21)+$0.01($0.10)$442.38 million$449.81 million      
10/26/2021Q3 2021($0.25)($0.20)+$0.05$0.14$435.29 million$408.74 million      
7/27/2021Q2 2021($0.11)$0.07+$0.18$0.39$448.84 million$501.69 million      
4/28/2021Q1 2021$0.07$0.09+$0.02$0.49$445.44 million$486.03 million    
2/25/2021Q4 2020($0.06)$0.12+$0.18($0.22)$447.17 million$452.12 million    
11/5/2020Q3 2020($0.01)$4.01+$4.02($3.43)$454.64 million$476.78 million    
8/4/2020Q2 2020($0.10)$0.07+$0.17$0.30$418.02 million$429.49 million  
4/29/2020Q1 2020$0.12$0.44+$0.32$0.32$468.77 million$502.07 million    
2/26/2020Q4$0.01$0.08+$0.07$0.10$461.88 million$454.44 million  

BioMarin Pharmaceutical Earnings - Frequently Asked Questions

When is BioMarin Pharmaceutical's earnings date?

BioMarin Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on BMRN's earnings history.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, September, 24th. The company provided EPS guidance of 3.100-3.250 for the period, compared to the consensus EPS estimate of 2.040. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

Did BioMarin Pharmaceutical beat their earnings estimates last quarter?

In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) missed the analysts' consensus estimate of $0.78 by $0.23 with a reported earnings per share (EPS) of $0.55. Learn more on analysts' earnings estimate vs. BMRN's actual earnings.

How can I listen to BioMarin Pharmaceutical's earnings conference call?

The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call

How can I read BioMarin Pharmaceutical's conference call transcript?

The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online. Read Transcript

How can I view BioMarin Pharmaceutical's earnings report?

BioMarin Pharmaceutical's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does BioMarin Pharmaceutical generate each year?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.59 billion.

How much profit does BioMarin Pharmaceutical generate each year?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $1.07 earnings per share over the last four quarters.

What is BioMarin Pharmaceutical's price-to-earnings ratio?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 49.54 and a forward price-to-earnings ratio of 27.57. The price/earnings-to-growth ratio is 0.81.

What is BioMarin Pharmaceutical's EPS forecast for next year?

BioMarin Pharmaceutical's earnings are expected to grow from $2.39 per share to $3.21 per share in the next year, which is a 34.31% increase.


`

More Earnings Resources from MarketBeat


This page (NASDAQ:BMRN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners